Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

CEL-SCI CORPORATION - CVM

8 Posts
| Omlaag ↓
  1. [verwijderd] 13 juni 2007 16:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bedrijf is laag geprijsd ( 0.87 ) en stuurt een brief naar de aandeelhouders. De moeite om de volledige tekst te lezen in onderstaande link.

    Misschien iets voor de toekomst als alles verloopt volgens plan. ( a market potential of $15 billion )

    CEL-SCI Corporation Releases Letter to Shareholders
    Wednesday June 13, 9:40 am ET

    VIENNA, Va., June 13 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM - News) to its shareholders:
    Dear Fellow Shareholders:

    So far 2007 has been an excellent year for CEL-SCI and its cancer product Multikine®. In January we received the US FDA go-ahead for the Phase III clinical trial with Multikine, a huge achievement for any drug, yet an even bigger achievement for a completely new type of drug such as our Multikine. We followed this up with a $15 million commitment to finance the Multikine manufacturing facility in Baltimore, Maryland and another $15 million in equity financing in April. In June we announced that we received orphan drug status from the FDA for Multikine. This designation brings many substantial benefits to the Company. I believe that the opportunity ahead for CEL-SCI is so compelling that I have continued to purchase CEL-SCI stock in the open market.

    In talking to investors it has become clear to me that few investors understand the enormous impact that our Multikine will have on the treatment of cancer if we can confirm in our Phase III study the impressive survival results we have seen in our Phase II trial. I believe that a background summary on Multikine is helpful for that reason.

    Market size: The current Phase III clinical trial pits Multikine plus
    the standard of care treatments against the standard of care treatments
    alone. A win for the Multikine treatment group would mean that every
    patient with advanced primary head and neck cancer is supposed to get
    Multikine. This would translate into a market potential of $15
    billion.

    biz.yahoo.com/prnews/070613/new047.ht...

    finance.yahoo.com/q/bc?s=CVM&t=1y
  3. [verwijderd] 29 januari 2008 00:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    CEL-SCI Corporation Releases Letter to Shareholders
    Monday January 28, 9:25 am ET

    VIENNA, Va., Jan. 28 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM - News) to its shareholders:
    Dear Fellow Shareholders:

    Our Company underwent a wonderful transformation last year from an intermediate stage company in its development to a late-stage biotechnology company. We are now one of a very select number of companies that have a completely novel medicine with blockbuster potential ready to go into a Phase III clinical trial. Our position is further enhanced by the fact that we are well capitalized and that we are building our own manufacturing facility close to Baltimore, Maryland. This facility will be capable of producing between $500 million and $600 million worth of Multikine® cancer drug per year, with the ability to triple production within about one year. The construction of the facility is scheduled for completion in the 3rd quarter of 2008.

    Company highlights of 2007:
    -- FDA clearance of Multikine for Phase III clinical trial in head and
    neck cancer
    -- Raised U.S. $15 million
    -- Multikine granted Orphan drug designation in U.S.
    -- Started build-out of manufacturing facility for Multikine to support
    upcoming Phase III study and commercial sale
    -- Started planning and pricing of our global clinical trial designed to
    lead to marketing approval for Multikine

    We expect 2008 to be another very positive year. We plan to contract with one or more Clinical Research Organizations to run our 800 patient Multikine Phase III trial which we expect to start in the last quarter of 2008. It will be run as an open label study (a study in which it is apparent which patients receive Multikine versus those who do not). The open label design will give us the opportunity to get early indications of how successful our study will be.

    We look forward to moving into the new facility later this year and we anxiously await the first indications from the open-label Phase III clinical trial with Multikine in advanced primary (not yet treated) head and neck cancer, representing a large unmet medical need and a disease in dire need of new and non-toxic treatments.

    Thank you for your continued support. We invite you to visit our new website at www.cel-sci.com to learn more about our breakthrough work in empowering immune defenses to defeat cancer.

    Sincerely yours,
    Geert Kersten Maximilian de Clara
    Chief Executive Officer President

    biz.yahoo.com/prnews/080128/nem044.ht...
8 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.285
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.166
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.876
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.151
Aedifica 2 829
Aegon 3.257 320.024
AFC Ajax 537 7.013
Affimed NV 2 5.740
ageas 5.843 109.775
Agfa-Gevaert 13 1.854
Ahold 3.536 73.978
Air France - KLM 1.024 34.304
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.696
Alfen 12 16.083
Allfunds Group 3 1.132
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 326
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.757
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.204
AMG 965 125.602
AMS 3 73
Amsterdam Commodities 303 6.512
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.107
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.580
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.098
Aroundtown SA 1 175
Arrowhead Research 5 9.252
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.541
ASML 1.762 76.647
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 322
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.638
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.660

Macro & Bedrijfsagenda

  1. 23 april

    1. Japan samengestelde inkoopmanagersindex april
    2. Novartis Q1-cijfers
    3. Renault Q1-cijfers
    4. Dui inkoopmanagersindex diensten april (voorlopig) volitaliteit verwacht
    5. Dui samengestelde inkoopmanagersindex april
    6. EU samengestelde inkoopmanagersindex april
    7. VK samengestelde inkoopmanagersindex april
    8. 3M Q1-cijfers
    9. GE Aerospace Q1-cijfers
    10. General Motors Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda